BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
Follow-Up Questions
Who is the CEO of BioSyent Inc?
Mr. Rene Goehrum is the Chairman of the Board of BioSyent Inc, joining the firm since 1996.
What is the price performance of BIOYF stock?
The current price of BIOYF is $8.67, it has decreased 0% in the last trading day.
What are the primary business themes or industries for BioSyent Inc?
BioSyent Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is BioSyent Inc market cap?
BioSyent Inc's current market cap is $99.6M
Is BioSyent Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for BioSyent Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
